| Title : Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma - Leineweber_2023_Front.Pharmacol_14_1124214 |
| Author(s) : Leineweber CG , Rabehl M , Pietzner A , Rohwer N , Rothe M , Pech M , Sangro B , Sharma R , Verslype C , Basu B , Sengel C , Ricke J , Schebb NH , Weylandt KH , Benckert J |
| Ref : Front Pharmacol , 14 :1124214 , 2023 |
| Abstract : Leineweber_2023_Front.Pharmacol_14_1124214 |
| ESTHER : Leineweber_2023_Front.Pharmacol_14_1124214 |
| PubMedSearch : Leineweber_2023_Front.Pharmacol_14_1124214 |
| PubMedID: 36937889 |
Leineweber CG, Rabehl M, Pietzner A, Rohwer N, Rothe M, Pech M, Sangro B, Sharma R, Verslype C, Basu B, Sengel C, Ricke J, Schebb NH, Weylandt KH, Benckert J (2023)
Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma
Front Pharmacol
14 :1124214
Leineweber CG, Rabehl M, Pietzner A, Rohwer N, Rothe M, Pech M, Sangro B, Sharma R, Verslype C, Basu B, Sengel C, Ricke J, Schebb NH, Weylandt KH, Benckert J (2023)
Front Pharmacol
14 :1124214